UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Blood advances, 2020-10, Vol.4 (19), p.4898-4911

2020

Link zum Volltext

Verfügbarkeit prüfen

Death Receptor Agonists as a Targeted Therapy for Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1701-1708

2010

Link zum Volltext

Verfügbarkeit prüfen

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Journal of clinical oncology, 2013-02, Vol.31 (6), p.759-765

2013

Link zum Volltext

Verfügbarkeit prüfen

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Clinical cancer research, 2013-04, Vol.19 (7), p.1902-1912

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-03, Vol.28 (9), p.1527-1533

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2007-06, Vol.25 (17), p.2369-2376

2007

Link zum Volltext

Verfügbarkeit prüfen

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

The New England journal of medicine, 2022-02, Vol.386 (7), p.640-654

2022

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab―FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization and Cell Cycle Regulation of the Major Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Latent Genes and Their Promoter

Journal of Virology, 1999-02, Vol.73 (2), p.1438-1446

1999

Link zum Volltext

Verfügbarkeit prüfen

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

The New England journal of medicine, 2023-07, Vol.389 (2), p.148-157

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Blood, 2017-12, Vol.130, p.2826-2826

2017

Link zum Volltext

Verfügbarkeit prüfen

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS7075-TPS7075

2016

Link zum Volltext

Verfügbarkeit prüfen

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3024-3024

2017

Link zum Volltext

Verfügbarkeit prüfen

Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7572-TPS7572

2017

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

International journal of colorectal disease, 2011-02, Vol.26 (2), p.173-181

2011

Link zum Volltext

Verfügbarkeit prüfen

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7559-7559

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3025-3025

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7512-7512

2017

Link zum Volltext

Verfügbarkeit prüfen

Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3023-3023

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Englisch
(38)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(13)
Oncology
(10)
Tumors
(9)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Chemotherapy
(6)
Male
(6)
Aged
(5)
Female
(5)
Middle Aged
(5)
Adult
(4)
Antibodies, Monoclonal - Therapeutic Use
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Colorectal Neoplasms - Drug Therapy
(4)
Colorectal Neoplasms - Genetics
(4)
Gastroenterology. Liver. Pancreas. Abdomen
(4)
Neoplasm Metastasis
(4)
Patients
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Death Receptor Agonists as a Targeted Therapy for Cancer

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Panitumumab―FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Characterization and Cell Cycle Regulation of the Major Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Latent Genes and Their Promoter

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL)

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)

Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)

Suchergebnisse filtern